Research programme: induced pluripotent stem cell therapeutics - Bayer/Evotec
Latest Information Update: 15 May 2024
At a glance
- Originator Bayer; Evotec SE
- Class Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cardiovascular disorders